Code
APH-CMET-01AX
Test
Active-Compendium
88360
Clinical
Pathology
<b>Preferred specimen (FFPE block):</b><br>
A formalin-fixed, paraffin-embedded (FFPE) tissue block is the preferred specimen type. Use 10% NBF fixative; do not use zinc or mercury fixatives.<br>
<b>If submitting slides (instead of a block):</b><br>
Submit the following. All slides cut at 4-5 microns. Please use positively-charged slides and 10% NBF fixative.<br>
<span style="margin-left: 20px;">H&E slide: One (1) unbaked, unstained slide for H&E staining (required)</span><br>
<span style="margin-left: 20px;">Cut Slides: Two (2) positively charged unstained slides for each IHC test/antibody ordered</span><br>
<b>Specimen adequacy:</b><br>
Tissue submitted must have >100 viable tumor cells present.<br>
<b>Specimen identification:</b><br>
Block and slide identifiers should be clearly written and match exactly with the specimen ID and specimen labeling as noted on the requisition.
A formalin-fixed, paraffin-embedded (FFPE) tissue block is the preferred specimen type. Use 10% NBF fixative; do not use zinc or mercury fixatives.<br>
<b>If submitting slides (instead of a block):</b><br>
Submit the following. All slides cut at 4-5 microns. Please use positively-charged slides and 10% NBF fixative.<br>
<span style="margin-left: 20px;">H&E slide: One (1) unbaked, unstained slide for H&E staining (required)</span><br>
<span style="margin-left: 20px;">Cut Slides: Two (2) positively charged unstained slides for each IHC test/antibody ordered</span><br>
<b>Specimen adequacy:</b><br>
Tissue submitted must have >100 viable tumor cells present.<br>
<b>Specimen identification:</b><br>
Block and slide identifiers should be clearly written and match exactly with the specimen ID and specimen labeling as noted on the requisition.
Flag Active
True
Orderable Test Description
<p>The c-MET CDx for NSCLC test is a companion diagnostic indicated as an aid in identifying non-squamous NSCLC patients who may be eligible for treatment with EMRELIS™ (telisotuzumab vedotin-tllv). Eligibility for EMRELIS treatment includes high HGFR (MET) protein overexpression, defined as ≥50% of tumor cells with strong (3+) staining using this assay.<br> <br>
This test implements the VENTANA MET (SP44) RxDx Assay, a qualitative
immunohistochemical assay using rabbit monoclonal anti-MET, clone SP44, intended for use in the assessment of HGFR (MET) protein expression in formalin-fixed paraffin
embedded (FFPE) non-squamous non-small cell lung cancer (NSCLC) specimens. This test recognizes MET proto-oncogene, receptor tyrosine kinase (MET) protein, also known as hepatocyte growth factor receptor and previously abbreviated as c-MET.</p>
This test implements the VENTANA MET (SP44) RxDx Assay, a qualitative
immunohistochemical assay using rabbit monoclonal anti-MET, clone SP44, intended for use in the assessment of HGFR (MET) protein expression in formalin-fixed paraffin
embedded (FFPE) non-squamous non-small cell lung cancer (NSCLC) specimens. This test recognizes MET proto-oncogene, receptor tyrosine kinase (MET) protein, also known as hepatocyte growth factor receptor and previously abbreviated as c-MET.</p>
Orderable Turn Around Time
1-2 Days
Orderable Biomarkers
NY Approved
True
Orderable Biomarkers JSON
{"Immunohistochemistry (IHC)": {"Expression": ["c-MET"]}}
Keywords string
cMET, c-met receptor tyrosine kinase, c-MET expression, c-MET IHC, cMET CDx, CDx c-MET CDx for NSCLC
Title URL
c-met-cdx-for-nsclc
TAT Details
Global: 2 Days
Tech-Only (stain only): 24 Hours
Storage and transportation
Slides may be stored at room temperature; transport with cold pack, making sure cold pack is not in direct contact with specimen.
NYS Clients: Please provide Date and Time of Collection.